Studies structured to deliver clear, actionable answers to complex scientific questions.
Explore thousands of proteins across tumor, tissue, plasma, CSF, saliva & urine
Directly measure thousands of proteins, including those on the tumor cell surface, in human tumors
Measure 120+ cytokines & chemokines from less than 25 μL of sample input
Integrate omics datasets to decipher heterogeneity in disease biology and patient response.
Ground every insight in human evidence to move discoveries forward with confidence.
Move beyond indirect proxies to measure proteins directly, with absolute quantitation.
Large-scale reference dataset to confirm & extend biomarker discoveries
Confirm preclinical findings in real-world cohorts
Comprehensive multi-omics data to map diverse human physiological states
Multi-scale analyses to maximize your omics study insights and deliver decision-ready findings.
Read out dynamic human physiology to reveal the metabolic states that determine disease trajectory, drug response & toxicity.
Maximize biological insights extracted from every precious sample
Characterize functional biology across critical dimensions directly in human tumors
Identify druggable tumor cell surface proteins using our SurfaceSeek™ workflow
Meet regulatory requirements for the analysis of samples collected from clinical trials
Comprehensively characterize druggable targets
Decipher dynamic factors of health & disease across large populations
How next-gen FFPE proteomics enables retrospective discovery in archived tissue, unlocking new biomarkers & targets.
Stay updated on Sapient’s scientific advancements, partnerships, and milestone highlights.
Have questions about multi-omics or what it’s like to work with Sapient?
See the discoveries uncovered from this multi-omics study led by a large industry-academia collaboration.
Learn more about our mission, our team, and how we’re leading biomarker discovery beyond the genome.
See what makes Sapient a unique partner for both deeper omics data generation and actionable insight delivery.
Explore opportunities to partner with our team on your next study.
Looking to be a part of something big?
Ready to move from discovery to decision-making, faster? Tell us about your needs.
Including for assays supporting primary and secondary endpoints
Modulates negatively TGFB1 signaling in keratinocytes.
"*" indicates required fields
Please don't include confidential details. We're happy to put a CDA in place before scoping.
By submitting, you agree to our privacy policy.
A member of our team will reply within 1 business day.
